Verastem (VSTM) Reiterated at Overweight by Cantor Fitzgerald as Key Readout is Near
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall Street tumbles as hot inflation data feeds worries about Fed rate hikes
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts VSTM Hot Sheet
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 34
Join SI Premium – FREE
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Verastem (NASDAQ: VSTM).
The analyst commented, "Verastem is fast approaching a key readout — initial Phase 1/2 dose expansion data on its KRAS G12D inhibitor VS-7375. The company will be hosting a webinar on October 14 to discuss data on ~20 patients with refractory pancreatic cancer (PDAC), ~20 patients with refractory lung cancer (NSCLC), and ~10 patients with refractory colorectal cancer (CRC)."
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $7.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fed Beige Book: Majority Of Districts Reported Some Growth
- Verastem Oncology prices $250M stock and warrant offering
- Utz Brands chairman emeritus Michael Rice dies at 83
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cantor Fitzgerald, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
